Vernalis plc (LON:VER)‘s stock had its “hold” rating reiterated by Panmure Gordon in a research note issued to investors on Monday. They currently have a GBX 31 ($0.41) price objective on the stock. Panmure Gordon’s price objective points to a potential upside of 63.16% from the stock’s current price.

A number of other brokerages also recently commented on VER. N+1 Singer reissued a “hold” rating and issued a GBX 28 ($0.37) price target on shares of Vernalis plc in a report on Friday, April 21st. Numis Securities Ltd reissued an “add” rating and issued a GBX 29 ($0.38) price target on shares of Vernalis plc in a report on Friday, April 21st. Stifel Nicolaus reduced their price target on Vernalis plc from GBX 29 ($0.38) to GBX 24 ($0.32) and set a “hold” rating for the company in a report on Friday, April 21st. Finally, RX Securities reissued a “buy” rating on shares of Vernalis plc in a report on Monday. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 39.40 ($0.52).

Vernalis plc (VER) traded down 10.53% during midday trading on Monday, reaching GBX 17.00. The company had a trading volume of 143,567 shares. The firm’s market capitalization is GBX 89.48 million. The firm’s 50-day moving average price is GBX 18.15 and its 200 day moving average price is GBX 22.70. Vernalis plc has a 12 month low of GBX 16.00 and a 12 month high of GBX 49.75.

TRADEMARK VIOLATION WARNING: “Vernalis plc (LON:VER) Stock Rating Reaffirmed by Panmure Gordon” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Analyst Recommendations for Vernalis plc (LON:VER)

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with's FREE daily email newsletter.